Efg Asset Management (Americas) Corp. Legend Biotech Corp Transaction History

Efg Asset Management (Americas) Corp.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 01, 2024	SELL	$57.25 - $69.74 $88,623 - $107,957	-1,548 Reduced 25.01%	4,641 $279,000
Q3 2023 Nov 09, 2023	SELL	$63.16 - $76.5 $40,738 - $49,342	-645 Reduced 9.44%	6,189 $415,000
Q2 2023 Aug 29, 2023	SELL	$46.28 - $75.01 $82,332 - $133,442	-1,779 Reduced 20.65%	6,834 $471,000
Q1 2023 May 04, 2023	BUY	$43.42 - $57.37 $64,044 - $84,620	1,475 Added 20.66%	8,613 $415,000
Q4 2022 Feb 09, 2023	BUY	$38.8 - $55.46 $22,310 - $31,889	575 Added 8.76%	7,138 $356,000
Q2 2022 Jul 13, 2022	SELL	$33.54 - $55.0 $39,409 - $64,625	-1,175 Reduced 15.18%	6,563 $361,000
Q1 2022 May 05, 2022	BUY	$31.02 - $48.18 $84,591 - $131,386	2,727 Added 54.42%	7,738 $281,000
Q4 2021 Jan 24, 2022	BUY	$41.14 - $56.98 $206,152 - $285,526	5,011 New	5,011 $234,000

225

74.3M

279K

350K

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $5.49B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

Get notified when there are updates to the investment portfolio of Efg Asset Management (Americas) Corp., based on Form 13F filings with the SEC.

Stay updated on Efg Asset Management (Americas) Corp. with notifications on news.